Forxiga is used by suitable adults with type 2 diabetes, heart failure or chronic kidney disease. Its active ingredient, dapagliflozin, helps the kidneys remove glucose, sodium and water in urine…
Forxiga is used by suitable adults with type 2 diabetes, heart failure or chronic kidney disease. Its active ingredient, dapagliflozin, helps the kidneys remove glucose, sodium and water in urine, supporting blood sugar control and reducing strain on the heart and kidneys.
Forxiga tablets are prescribed for type 2 diabetes, heart failure and chronic kidney disease in suitable adults. They contain dapagliflozin, an SGLT2 inhibitor that helps the kidneys remove glucose, sodium and water through urine. This can improve glycaemic control and reduce strain on the heart and kidneys.
Forxiga is used in three main clinical settings:
The same kidney mechanism explains why Forxiga has uses beyond blood sugar control. Removing sodium and water reduces fluid congestion, while changes in pressure within the kidney’s filtration system may reduce stress on the glomeruli. The EMA product information and current UK prescribing practice describe dapagliflozin as an SGLT2 inhibitor for diabetes, heart failure and chronic kidney disease [1].
Forxiga is not suitable for every person with these conditions. Kidney function, blood pressure, hydration, current medicines and the reason for treatment all influence the prescribing decision.
Forxiga tablets contain dapagliflozin, an SGLT2 inhibitor. The active ingredient helps the kidneys remove glucose, sodium and water through urine. This action can support blood sugar control and reduce strain on the heart and kidneys in suitable adults.
Dapagliflozin blocks sodium-glucose co-transporter 2, known as SGLT2, in the proximal renal tubule. SGLT2 normally reabsorbs filtered glucose and sodium back into the bloodstream. When this transporter is inhibited, more glucose remains in the urine and more sodium passes out of the body.
The resulting effects include:
SGLT2 inhibition differs from metformin, which mainly reduces hepatic glucose production and improves insulin sensitivity. It also differs from insulin, which directly increases glucose uptake and lowers blood glucose through hormone replacement. These mechanisms can be combined only when the prescribing plan accounts for kidney function, hypoglycaemia risk and other treatments.
Forxiga is taken by mouth as a tablet. The regimen for the selected strength should be confirmed with a healthcare professional before starting, because the appropriate plan depends on the indication, kidney function and concurrent medicines.
Practical administration points include:
A tablet should not be split, crushed or chewed unless the prescriber or dispensing instructions specifically allow this. Whole-tablet administration supports consistent dosing and avoids confusion about the prescribed amount.
People taking Forxiga should know the signs of dehydration: unusual thirst, dry mouth, dizziness when standing, weakness and reduced urination. Fluid advice is different for people with advanced heart failure or kidney disease, so forcing extra water can also be inappropriate.
Clinicians choose treatment according to the condition being treated, kidney function, cardiovascular history, hypoglycaemia risk, weight goals, frailty and current therapy.
| Treatment approach | Main pharmacological action | Clinical role |
|---|---|---|
| Forxiga — dapagliflozin | Blocks SGLT2 and increases urinary glucose and sodium loss | Type 2 diabetes, heart failure and chronic kidney disease in eligible adults |
| Empagliflozin | Blocks SGLT2 and produces similar renal glucose and sodium loss | Type 2 diabetes, heart failure and selected kidney disease indications |
| Metformin-based treatment | Reduces hepatic glucose production and improves insulin sensitivity | Common foundation treatment for type 2 diabetes when suitable |
Dapagliflozin and empagliflozin belong to the same SGLT2 inhibitor class, but the choice can depend on the licensed indication, kidney function thresholds, local prescribing guidance and the person’s response. Metformin works through a different pathway and does not produce the same diuretic effect.
Combination treatment can improve glucose control, yet every additional medicine increases the need to review interactions, kidney function and tolerability. For example, combining an SGLT2 inhibitor with insulin may require attention to hypoglycaemia and sick-day management, while combining it with a diuretic may increase the risk of dehydration.
Several practical errors can reduce treatment safety or make side effects more likely:
Alcohol excess, acute infection and reduced food intake can increase metabolic stress. The combination of illness, dehydration and low insulin availability is a recognised setting for ketoacidosis.
Forxiga is not suitable for you if you have had a serious allergic reaction to dapagliflozin or another ingredient in the prescribed tablet. It is also unsuitable for people with diabetic ketoacidosis or suspected ketoacidosis, which requires urgent medical treatment rather than another dose.
Extra caution or specialist review is needed in the following situations:
Forxiga may increase the fluid-losing effect of diuretics. It can also increase hypoglycaemia risk when used with insulin or insulin-releasing medicines. The MHRA has highlighted the need for clear recognition of diabetic ketoacidosis symptoms with SGLT2 inhibitors, including presentations where glucose is not markedly elevated [4].
Do not take Forxiga if you have previously had a serious allergic reaction to dapagliflozin or if you currently have, or may have, diabetic ketoacidosis. Speak with a clinician before using it if you have unstable kidney problems, frequent dehydration or fainting, are pregnant or breastfeeding, have type 1 diabetes, or often develop genital infections. Your treatment also needs careful review if you use insulin, a sulfonylurea or diuretics, or if you are going to have surgery or prolonged fasting.
Forxiga changes the amount of glucose and water leaving the body. That explains both its therapeutic effects and its most relevant adverse reactions.
Common or clinically recognised problems include:
Genital fungal infections can cause itching, soreness, redness or unusual discharge. Urinary infection symptoms may include burning during urination, frequent urination, lower abdominal discomfort or fever. These problems need assessment if they are severe, recurrent or accompanied by back pain or systemic symptoms.
Low blood glucose is less likely with Forxiga alone than with insulin or sulfonylureas. The risk rises when Forxiga is combined with treatments that stimulate insulin release or provide insulin directly. Symptoms may include sweating, shaking, hunger, palpitations, confusion and unusual weakness.
Rare but serious reactions require urgent medical attention:
The FDA prescribing information highlights ketoacidosis, volume depletion, genital infections, urinary infections and necrotising fasciitis as important safety risks associated with dapagliflozin [2].
In clinical practice, prescribers usually assess more than the glucose reading before starting Forxiga. They review kidney function, blood pressure, hydration, previous urinary or genital infections, diuretic treatment and the patient’s ability to recognise illness.
A doctor may explain that the medicine can provide benefits gradually rather than producing a noticeable sensation. Better glucose readings may appear before the person feels any different. In heart failure or chronic kidney disease, the purpose may be reducing future admissions or slowing decline, so daily adherence matters even when symptoms are stable.
The Kidney Disease: Improving Global Outcomes guideline supports the role of SGLT2 inhibitors in appropriate adults with chronic kidney disease, subject to clinical criteria and contraindications [3]. Treatment may be paused during serious illness, prolonged fasting, major dehydration or surgery. The timing depends on the person’s condition and the planned procedure.
Active diabetic ketoacidosis rules out further Forxiga dosing and requires urgent medical treatment. A previous severe allergic reaction to dapagliflozin or an excipient is another clear reason not to take it. The 2024 MHRA safety information stresses that ketoacidosis can occur with only moderately raised glucose, so glucose alone cannot exclude the problem. A clinician should also assess severe kidney impairment, type 1 diabetes and recurrent dehydration before prescribing.
Stop and seek urgent medical assessment for vomiting, abdominal pain, deep or rapid breathing, confusion, severe weakness or unusual sleepiness, because these may indicate ketoacidosis. Urgent review is also needed for fainting, inability to keep fluids down, very little urine, severe genital or perineal pain, or rapidly spreading swelling and redness. The 2025 EMA product information identifies these reactions as serious safety concerns, with guidance updated in its current regulatory materials [5]. Do not restart treatment after such symptoms until a clinician has provided a clear plan.
The tablet should be swallowed whole unless a prescriber or dispensing instruction specifically permits another method. Splitting, crushing or chewing can make administration less consistent and may cause confusion about the intended dose. The 2025 EMA product information describes oral tablet administration and supports following the prescribed form rather than altering it. This is also useful for people who organise medicines into weekly pill boxes, because the tablet should remain identifiable and intact.
Forxiga can generally be taken with food or without food, provided it is taken at the prescribed interval. Taking it at a consistent time may make increased urination easier to manage. Timing can affect tolerability. The NICE type 2 diabetes guidance available in 2026 supports individualised medicine schedules that account for concurrent treatments, kidney function and tolerability. People with fluid restrictions should follow their heart or kidney care plan rather than deliberately increasing fluids.
Do not increase the dose independently when glucose readings, swelling, breathlessness or kidney results do not improve as expected. The prescriber may review adherence, kidney function, diet, fluid status, other medicines and whether the original treatment goal remains appropriate. NICE guidance updated before 2026 recommends treatment review using clinical response and risk factors rather than a single home reading. Seek urgent help for worsening breathlessness, chest pain, severe swelling, vomiting or ketoacidosis symptoms.
Take the missed tablet when remembered if there is enough time before the next scheduled dose. If the next dose is due soon, skip the missed dose and continue with the regular schedule; do not take two doses together. NHS medicines advice used in 2026 supports avoiding double dosing after a missed oral medicine dose unless a specific medicine instruction says otherwise. Vomiting shortly after administration, prolonged diarrhoea and fasting require separate sick-day advice rather than automatic replacement dosing.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
My morning readings became steadier after the first few weeks, and I noticed I was urinating more often. The extra bathroom visits were manageable when I took it early, but thirst became a problem during a week of hot weather.
Sheffield Several months 26 Oct 2026I felt less swollen around my ankles after a few weeks and had more confidence walking outside. I became light-headed after a stomach bug and needed the treatment plan reviewed, so I learned not to carry on as normal during vomiting and diarrhoea.
Cardiff Several weeks 30 Sept 2026The tablet was easy to take and my glucose results improved. I had a genital infection during the second month, which was unpleasant but treated. My clinician reviewed the rest of my medicines and gave me clearer instructions for sick days.
Portsmouth Several months 14 Oct 2026
